'Right-to-try' bill fails to muster votes, dies in the House (for now)
The controversial right-to-try bill, a divisive piece of legislation that would have given terminally ill patients access to experimental drugs without FDA authorization, was rejected by the House Tuesday after failing to get enough backers for the vote.
The bill died on a vote of 259 to 140, short of the necessary two-thirds support from the chamber.
The vote came after a contentious debate among lawmakers and biopharma alike, centering on the appropriate balance between a patient’s freedom of choice and the regulatory oversight needed for that patient’s safety.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
